SYNCHRONIZING AND COMMERCIAL OPERATION Sample Clauses

SYNCHRONIZING AND COMMERCIAL OPERATION. 2.10.1 After EGAT provides notice pursuant to Section 2.9.6(i), the Generator shall conduct the Unit synchronizing tests set out in Paragraph 3.5 of Part B of Schedule 18. EGAT shall review the results of such Unit synchronizing tests. After receiving the results of such testing, EGAT shall either (i) within one (1) day provide the Generator with written notice that the test requirements set out in Paragraph 3.5 of Part B of Schedule 18 have been met, or (ii) within seven (7) days provide the Generator with a written report describing any areas where, in EGAT's reasonable opinion, such requirements have not been met. If EGAT reports that the Unit has not met the requirements for notice pursuant to subclause (i) of this Section, the Generator shall determine and remedy the cause of such failure. The remedy and cost of the remedy shall be borne by the Generator. The Generator shall notify EGAT when further testing pursuant to Paragraph 3.5 of Part B of Schedule 18 can take place. Such further testing shall commence on a date agreed by the Parties which shall be not more than seven (7) days after the Generator so notifies EGAT. Such further testing and EGAT's review of the results thereof shall proceed pursuant to this Section. The Generator shall be allowed to synchronize on an agreed date occurring after EGAT provides notice pursuant to subclause (i) of this Section 2.10.1, but no more than one hundred and eighty (180) days before the Commercial Operation Date of the Unit the Parties anticipate to be set pursuant to Section 2.10.2.
Sample 1
AutoNDA by SimpleDocs

Related to SYNCHRONIZING AND COMMERCIAL OPERATION

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Program Management (WBS 1.1) All components of the Project Management Plan as implemented for the Base Contract and Options 1-4 will be reviewed and amended to reflect specific needs for Option 5 and the outcome of continuous process improvement evaluations.

  • Project Management With respect to each Project Plan, each party will appoint a project manager who will be the party responsible for overseeing the Project Plan.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

  • TECHNICAL SUPPORT SERVICES 2.1 The technical support services (the "Services"): Party A agrees to provide to Party B the relevant services requested by Party B, which are specified in Exhibit 1 attached hereto ("Exhibit 1").

  • Marketing Services The Manager shall provide advice and assistance in the marketing of the Vessels, including the identification of potential customers, identification of Vessels available for charter opportunities and preparation of bids.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Support Services Other than the assistance provided in the Information, the BNPP Entities do not offer any support services in connection with the Software.

Time is Money Join Law Insider Premium to draft better contracts faster.